Gianluigi Savarese1, Hong Xu2, Marco Trevisan2, Ulf Dahlström3, Patrick Rossignol4, Bertram Pitt5, Lars H Lund6, Juan J Carrero2. 1. Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden. 2. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. 3. Departments of Cardiology Medical and Health Sciences, Linkoping University, Linkoping, Sweden. 4. Université de Lorraine, INSERM CIC-P 1433, Centre Hospitalier Régional Universitaire de Nancy, and INSERM U1116, FCRIN INI-Cardiovascular and Renal Clinical Trialists, Nancy, France. 5. Department of Medicine, University of Michigan, Ann Arbor, Michigan. 6. Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden. Electronic address: Lars.Lund@alumni.duke.edu.
Abstract
OBJECTIVES: This study investigated 1-year incidence and predictors of dyskalemia (dysK) and its outcome associations in heart failure with preserved ejection fraction (HFpEF), HF with mid-range EF (HFmrEF), and HF with reduced EF (HFrEF). BACKGROUND: DysK in real-world HF is insufficiently characterized. Fear of dyskalemia may lead to underuse or underdosing of renin-angiotensin-aldosterone system inhibitors. METHODS: Patients enrolled in the SwedeHF (Swedish Heart Failure) Registry from 2006 to 2011 in Stockholm, Sweden were included in the analyses. Multivariate Cox regression analysis identified independent predictors of dysK within 1 year. Time-dependent Cox models assessed outcomes associated with incident dysK (all-cause death, HF, and other cardiovascular disease [CVD] hospitalizations) within 1 year from baseline. RESULTS: Of 5,848 patients, 24.4% experienced hyperkalemia (hyperK [K >5.0 mmol/l]) at least once, and 10.2% had moderate or severe hyperK (K >5.5 mmol/l). Adjusted risk of moderate or severe hyperK was highest in HFpEF and HFmrEF. Similarly, 20.3% of patients had at least one episode of hypokalemia (hypoK [<3.5 mmol/l]), and 3.7% had severe hypoK (<3.0 mmol/l). Adjusted risk of any hypoK was highest in HFpEF. Independent predictors of both hyperK and hypoK were sex, baseline potassium and estimated glomerular filtration rate, low hemoglobin, chronic obstructive pulmonary disease (COPD), inpatient status, and higher New York Heart Association functional class. Incident dysK was associated with increased risk of mortality. Furthermore, hypoK was associated with increased CVD hospitalizations (HF-related excluded). There was no association between dysK and HF hospitalization risk, regardless of EF. CONCLUSIONS: DysK is common in HF and is associated with increased mortality. Risk of moderate or severe hyperK was highest in HFpEF and HFmrEF, whereas risk of hypoK was highest in HFpEF. HF severity, low hemoglobin, COPD, baseline high and low potassium, and low eGFR were relevant predictors of dysK occurrence.
OBJECTIVES: This study investigated 1-year incidence and predictors of dyskalemia (dysK) and its outcome associations in heart failure with preserved ejection fraction (HFpEF), HF with mid-range EF (HFmrEF), and HF with reduced EF (HFrEF). BACKGROUND: DysK in real-world HF is insufficiently characterized. Fear of dyskalemia may lead to underuse or underdosing of renin-angiotensin-aldosterone system inhibitors. METHODS:Patients enrolled in the SwedeHF (Swedish Heart Failure) Registry from 2006 to 2011 in Stockholm, Sweden were included in the analyses. Multivariate Cox regression analysis identified independent predictors of dysK within 1 year. Time-dependent Cox models assessed outcomes associated with incident dysK (all-cause death, HF, and other cardiovascular disease [CVD] hospitalizations) within 1 year from baseline. RESULTS: Of 5,848 patients, 24.4% experienced hyperkalemia (hyperK [K >5.0 mmol/l]) at least once, and 10.2% had moderate or severe hyperK (K >5.5 mmol/l). Adjusted risk of moderate or severe hyperK was highest in HFpEF and HFmrEF. Similarly, 20.3% of patients had at least one episode of hypokalemia (hypoK [<3.5 mmol/l]), and 3.7% had severe hypoK (<3.0 mmol/l). Adjusted risk of any hypoK was highest in HFpEF. Independent predictors of both hyperK and hypoK were sex, baseline potassium and estimated glomerular filtration rate, low hemoglobin, chronic obstructive pulmonary disease (COPD), inpatient status, and higher New York Heart Association functional class. Incident dysK was associated with increased risk of mortality. Furthermore, hypoK was associated with increased CVD hospitalizations (HF-related excluded). There was no association between dysK and HF hospitalization risk, regardless of EF. CONCLUSIONS: DysK is common in HF and is associated with increased mortality. Risk of moderate or severe hyperK was highest in HFpEF and HFmrEF, whereas risk of hypoK was highest in HFpEF. HF severity, low hemoglobin, COPD, baseline high and low potassium, and low eGFR were relevant predictors of dysK occurrence.
Authors: Antonio Olry de Labry Lima; Óscar Díaz Castro; Jorge M Romero-Requena; M de Los Reyes García Díaz-Guerra; Virginia Arroyo Pineda; M Belén de la Hija Díaz; Meritxell Ascanio; Josep Darbà; Josep M Cruzado Journal: Clin Kidney J Date: 2021-04-07
Authors: Ozan Unlu; Emily B Levitan; Evgeniya Reshetnyak; Jerard Kneifati-Hayek; Ivan Diaz; Alexi Archambault; Ligong Chen; Joseph T Hanlon; Mathew S Maurer; Monika M Safford; Mark S Lachs; Parag Goyal Journal: Circ Heart Fail Date: 2020-10-13 Impact factor: 8.790
Authors: João Pedro Ferreira; Ulrik M Mogensen; Pardeep S Jhund; Akshay S Desai; Jean-Lucien Rouleau; Michael R Zile; Patrick Rossignol; Faiez Zannad; Milton Packer; Scott D Solomon; John J V McMurray Journal: Eur J Heart Fail Date: 2020-09-29 Impact factor: 15.534